Logo image of RIGL

RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

USA - NASDAQ:RIGL - US7665597024 - Common Stock

34.02 USD
-0.43 (-1.25%)
Last: 9/23/2025, 8:09:45 PM
34.3884 USD
+0.37 (+1.08%)
After Hours: 9/23/2025, 8:09:45 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to RIGL. RIGL was compared to 538 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make RIGL a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
In the past 5 years RIGL reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

RIGL has a Return On Assets of 47.32%. This is amongst the best in the industry. RIGL outperforms 99.63% of its industry peers.
RIGL has a better Return On Equity (119.39%) than 99.26% of its industry peers.
RIGL has a Return On Invested Capital of 68.80%. This is amongst the best in the industry. RIGL outperforms 99.81% of its industry peers.
Industry RankSector Rank
ROA 47.32%
ROE 119.39%
ROIC 68.8%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

RIGL's Profit Margin of 36.51% is amongst the best of the industry. RIGL outperforms 97.21% of its industry peers.
With an excellent Operating Margin value of 39.04%, RIGL belongs to the best of the industry, outperforming 98.51% of the companies in the same industry.
RIGL has a better Gross Margin (91.52%) than 92.19% of its industry peers.
RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 39.04%
PM (TTM) 36.51%
GM 91.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for RIGL has been increased compared to 1 year ago.
RIGL has less shares outstanding than it did 5 years ago.
The debt/assets ratio for RIGL has been reduced compared to a year ago.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RIGL has an Altman-Z score of -2.52. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
RIGL has a Altman-Z score (-2.52) which is comparable to the rest of the industry.
RIGL has a debt to FCF ratio of 0.91. This is a very positive value and a sign of high solvency as it would only need 0.91 years to pay back of all of its debts.
RIGL has a better Debt to FCF ratio (0.91) than 94.80% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that RIGL is not too dependend on debt financing.
RIGL has a Debt to Equity ratio of 0.46. This is in the lower half of the industry: RIGL underperforms 72.12% of its industry peers.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 0.91
Altman-Z -2.52
ROIC/WACC6.73
WACC10.22%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.02 indicates that RIGL has no problem at all paying its short term obligations.
RIGL's Current ratio of 2.02 is on the low side compared to the rest of the industry. RIGL is outperformed by 74.16% of its industry peers.
A Quick Ratio of 1.90 indicates that RIGL should not have too much problems paying its short term obligations.
RIGL has a Quick ratio of 1.90. This is in the lower half of the industry: RIGL underperforms 74.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.9
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 729.07%, which is quite impressive.
The Revenue has grown by 105.62% in the past year. This is a very strong growth!
Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)729.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5566.67%
Revenue 1Y (TTM)105.62%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%176.01%

3.2 Future

RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.86% yearly.
RIGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.40% yearly.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 -10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

RIGL is valuated cheaply with a Price/Earnings ratio of 6.29.
RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 97.77% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. RIGL is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.83 indicates a reasonable valuation of RIGL.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaply inside the industry as 97.40% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (22.87), we can say RIGL is valued rather cheaply.
Industry RankSector Rank
PE 6.29
Fwd PE 8.83
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

97.96% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 98.33% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.28
EV/EBITDA 4.74
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 61.96% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (9/23/2025, 8:09:45 PM)

After market: 34.3884 +0.37 (+1.08%)

34.02

-0.43 (-1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners79.46%
Inst Owner Change-1.13%
Ins Owners2.59%
Ins Owner Change1.25%
Market Cap610.32M
Analysts76.67
Price Target39.1 (14.93%)
Short Float %11.49%
Short Ratio3.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)308.53%
Min EPS beat(2)24.64%
Max EPS beat(2)592.43%
EPS beat(4)4
Avg EPS beat(4)440.39%
Min EPS beat(4)24.64%
Max EPS beat(4)1076.54%
EPS beat(8)7
Avg EPS beat(8)241.24%
EPS beat(12)11
Avg EPS beat(12)177.31%
EPS beat(16)13
Avg EPS beat(16)133.23%
Revenue beat(2)2
Avg Revenue beat(2)15.63%
Min Revenue beat(2)12.08%
Max Revenue beat(2)19.17%
Revenue beat(4)4
Avg Revenue beat(4)17.43%
Min Revenue beat(4)9.15%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)9.33%
Revenue beat(12)10
Avg Revenue beat(12)13.36%
Revenue beat(16)11
Avg Revenue beat(16)9.9%
PT rev (1m)13.61%
PT rev (3m)13.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)307.02%
EPS NY rev (1m)0%
EPS NY rev (3m)380.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)22.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.78%
Valuation
Industry RankSector Rank
PE 6.29
Fwd PE 8.83
P/S 2.28
P/FCF 9.28
P/OCF 9.27
P/B 7.45
P/tB 10.9
EV/EBITDA 4.74
EPS(TTM)5.41
EY15.9%
EPS(NY)3.85
Fwd EY11.32%
FCF(TTM)3.67
FCFY10.78%
OCF(TTM)3.67
OCFY10.79%
SpS14.93
BVpS4.57
TBVpS3.12
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 47.32%
ROE 119.39%
ROCE 87.08%
ROIC 68.8%
ROICexc 704.92%
ROICexgc N/A
OM 39.04%
PM (TTM) 36.51%
GM 91.52%
FCFM 24.56%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score6
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 0.91
Debt/EBITDA 0.35
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 15.13
Cash Conversion 61.51%
Profit Quality 67.26%
Current Ratio 2.02
Quick Ratio 1.9
Altman-Z -2.52
F-Score6
WACC10.22%
ROIC/WACC6.73
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)729.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5566.67%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue 1Y (TTM)105.62%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%176.01%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
EBIT growth 1Y1259.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year178.6%
EBIT Next 3Y76.86%
EBIT Next 5YN/A
FCF growth 1Y235.34%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y297.38%
OCF growth 3Y74.92%
OCF growth 5YN/A